Leap Therapeutics, Inc. (LPTX)

Compare

0.3400

+0.0487

+(16.72%)

At close: 4:00:01 PM EDT

0.3252

-0.01

(-4.35%)

After hours: 5:11:21 PM EDT

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Leap Therapeutics, Inc. (NASDAQ:LPTX) presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm). The trial enrolled patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease. The updated analysis shared on Wednesday includes the overall r

Benzinga 7 days ago

LPTX
+16.72%
Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial

Leap Therapeutics (LPTX) said Wednesday that updated findings from its phase 2 trial indicate that s

PREMIUM
MT Newswires 7 days ago

LPTX
+16.72%
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.

PR Newswire 7 days ago

LPTX
+16.72%
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study (NCT05480306), a Phase 2, open-label, global study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with advanced microsatellite stable (MSS) colorectal

PR Newswire 7 days ago

LPTX
+16.72%
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (CRC), and initial data from Part C of the DisTinGuish study evaluating sirexatamab in combination with tislelizumab and chemotherapy in first-line

PR Newswire 2 months ago

LPTX
+16.72%
Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

PR Newswire 2 months ago

LPTX
+16.72%
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York, NY.

PR Newswire 4 months ago

LPTX
+16.72%
Leap Therapeutics Reports Third Quarter 2024 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024.

PR Newswire 4 months ago

LPTX
+16.72%
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment of 188 patients has been completed in the randomized controlled Part B of the DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (CRC).

PR Newswire 5 months ago

LPTX
+16.72%
Leap Therapeutics Reports Second Quarter 2024 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024.

PR Newswire 7 months ago

LPTX
+16.72%
Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress

Significant Reduction in Net Loss and Strategic Clinical Advancements

GuruFocus.com 10 months ago

LPTX
+16.72%
Leap Therapeutics Reports First Quarter 2024 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024.

PR Newswire 10 months ago

LPTX
+16.72%
Pipeline Moves: Investigator-led trial of Lilly’s merestinib in solid tumours terminated

The Clinical Trials Arena team also evaluates assets in infectious diseases,

Clinical Trials Arena 10 months ago

GLDAF

LLY

LPTX
+16.72%
Leap Therapeutics Announces $40 Million Private Placement

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock issuable upon exercise

PR Newswire 11 months ago

LPTX
+16.72%

Performance Overview

Return	LPTX	S&P 500 (^GSPC)
YTD	-88.17%	-3.58%
1-Year	-87.07%	+8.94%
3-Year	-98.15%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Leap Therapeutics, Inc. (LPTX)

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Reports Second Quarter 2024 Financial Results

Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress

Leap Therapeutics Reports First Quarter 2024 Financial Results

Pipeline Moves: Investigator-led trial of Lilly’s merestinib in solid tumours terminated

Leap Therapeutics Announces $40 Million Private Placement

Performance Overview